Testosterone Cypionate FDA Approval History

What Is the Full FDA Approval History of Testosterone Cypionate?

Testosterone cypionate has been FDA-approved for over four decades, making it one of the longest-standing androgen therapies in US clinical practice. The original NDA 013753 was granted in 1979 for intramuscular treatment of male hypogonadism. The branded product Depo-Testosterone (Pfizer) anchored that original filing, and generic manufacturers entered the market as patents expired.

The FDA's Drugs@FDA database lists NDA 013753 as the reference NDA, with supplemental approvals tracking each label update [1]. Understanding this history matters because each label revision reflects new safety data that directly affects how clinicians prescribe and how patients use this medication.

The 1979 Initial Approval

The original label approved testosterone cypionate solely for males with primary hypogonadism (congenital or acquired testicular failure) and hypogonadotropic hypogonadism (congenital or acquired conditions where the hypothalamic-pituitary axis fails to stimulate adequate endogenous testosterone) [1]. The approved dosing range of 50 to 400 mg intramuscularly every 2 to 4 weeks reflected pharmacokinetic data showing a serum half-life of approximately 8 days for the cypionate ester [2].

At that time, the label carried no boxed warning. Adverse-effect language focused primarily on virilization, fluid retention, and hepatic effects consistent with the broader androgen class. The cardiovascular and thrombotic language that dominates today's label did not yet exist in this form.

Generic Entry and Market Expansion

Multiple Abbreviated New Drug Applications (ANDAs) followed the original NDA as exclusivity windows closed. Today, Depo-Testosterone (Pfizer) and numerous generic versions share the market [1]. All approved products reference the same clinical basis but must meet the same bioequivalence and labeling standards as the reference listed drug.

How Has the Testosterone Cypionate Label Changed Over Time?

The prescribing information for testosterone cypionate has been revised substantially since 1979, with the most consequential updates occurring between 2010 and 2018. Each revision reflects either new post-market safety signals, changes to the DEA schedule, or guidance from FDA drug-safety communications.

The Schedule III DEA Classification

Testosterone cypionate was placed in Schedule III of the Controlled Substances Act under the Anabolic Steroid Control Act of 1990, which took effect in 1991 [3]. This classification mandated specific labeling language about abuse potential, physical and psychological dependence, and the legal consequences of non-prescribed use. The current label explicitly states that testosterone is subject to Schedule III restrictions and must be dispensed under a valid prescription [3].

The Anabolic Steroid Control Act of 2004 broadened the list of scheduled anabolic steroids but did not reclassify testosterone itself, leaving cypionate at Schedule III [4]. Clinicians prescribing testosterone cypionate for legitimate hypogonadism are legally protected, but must maintain appropriate DEA registration and documentation [4].

The Boxed Warning on Abuse and Dependence

The most prominent label change visible on the current prescribing information is the boxed warning. It reads, in part: "Androgens may cause virilization of the female genitalia of the female fetus. Serious pulmonary oil microembolism (POME) reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope, have been reported." The full label, accessible via FDA Drugs@FDA [1], also describes dependence and abuse under the boxed language.

POME events specifically prompted label strengthening. FDA Adverse Event Reporting System (FAERS) data accumulated across the 2000s showed a consistent signal of respiratory distress following intramuscular testosterone injections, leading FDA to require that each injection be administered in a healthcare setting capable of managing anaphylaxis [5].

2015 FDA Drug Safety Communication on Cardiovascular Risk

The most clinically significant post-market label action came in March 2015, when the FDA issued a drug safety communication requiring a label change for all testosterone products, including cypionate [6]. The FDA mandated:

• A general statement that testosterone is approved only for men with low testosterone caused by a medical condition, not for age-related testosterone decline.
• A warning about a possible increased risk of heart attack and stroke in men taking testosterone products [6].

The FDA's 2015 communication was triggered by two observational studies published in PLOS ONE (Finkle et al., 2014, N=55,593) and JAMA Internal Medicine (Vigen et al., 2013, N=8,709), both of which reported elevated cardiovascular event rates in testosterone users [6]. Neither study was a randomized trial, and both had methodological limitations, but their aggregate signal was sufficient for FDA to act under its post-market authority [6].

What Does the Current Testosterone Cypionate Label Say?

The current prescribing information for testosterone cypionate covers indications, dosing, warnings, drug interactions, and special populations. Knowing its contents is essential for clinicians who prescribe this drug and for patients trying to understand what is and is not FDA-approved in their treatment plan.

Approved Indications

The label approves testosterone cypionate for males with:

1. Primary hypogonadism (congenital or acquired), including Klinefelter syndrome, bilateral torsion, orchitis, vanishing testes syndrome, orchiectomy, hemochromatosis, and pituitary-hypothalamic injury.
2. Hypogonadotropic hypogonadism (congenital or acquired), including idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation [1].

Off-label uses, including testosterone therapy in women, gender-affirming hormone therapy, and athletic performance, are not approved indications and carry no FDA-sanctioned dosing guidance [7].

Dosing Information

The label specifies 50 to 400 mg administered intramuscularly every 2 to 4 weeks [1]. This wide range reflects significant individual variation in pharmacokinetics. In clinical practice, many providers use weekly or biweekly dosing at lower doses (100 to 200 mg) to reduce peak-to-trough serum fluctuations, a pattern supported by pharmacokinetic modeling but not directly addressed by the label [2].

The Endocrine Society 2018 Clinical Practice Guideline on Male Hypogonadism states: "We suggest using testosterone preparations that maintain testosterone levels in the normal range consistently, rather than preparations that produce supraphysiologic peaks" [8]. This recommendation implicitly favors the lower-dose, higher-frequency approach that many prescribers have adopted outside the strict label dosing schedule.

Key Warnings and Precautions

The current label includes the following specific warnings [1]:

• Polycythemia: Testosterone stimulates erythropoiesis. Hematocrit should be checked at 3 to 6 months and annually thereafter. If hematocrit exceeds 54%, therapy should be interrupted [8].
• Venous thromboembolism (VTE): Cases of VTE, including deep vein thrombosis and pulmonary embolism, have been reported. The label advises discontinuation if VTE is suspected [1].
• Sleep apnea: Testosterone therapy may worsen pre-existing obstructive sleep apnea, particularly in obese men [8].
• Lipid effects: Testosterone may decrease serum HDL-C. Lipid monitoring is recommended [1].
• Infertility: Exogenous testosterone suppresses gonadotropins (LH and FSH) via negative feedback, reducing or eliminating sperm production. This effect is reversible in most men within 6 to 18 months of discontinuation [9].

What Does Post-Market Surveillance Reveal About Testosterone Cypionate Safety?

Post-market surveillance has produced the most substantive safety data on testosterone cypionate, given that the original 1979 approval predated the large-scale randomized trial infrastructure we have today.

The T-Trials (NEJM, 2016)

The Testosterone Trials (T-Trials) represent the most rigorous post-market safety and efficacy assessment of testosterone therapy in older men. Published in the New England Journal of Medicine in 2016 (N=788, mean age 72 years), the T-Trials used testosterone gel rather than cypionate injections, but the findings informed FDA's understanding of the class as a whole [10].

The T-Trials found that testosterone therapy increased hemoglobin by 1.0 g/dL vs. 0.1 g/dL with placebo and significantly improved sexual function scores, bone density, and walking distance [10]. The study also reported that coronary artery noncalcified plaque volume increased more in the testosterone group than placebo (41 vs. 13 mm3, P<0.001), a finding that intensified regulatory scrutiny of cardiovascular endpoints across all testosterone formulations [10].

These results did not trigger a label change specific to testosterone cypionate, but they contributed to the ongoing FDA requirement that all testosterone labeling carry cardiovascular risk language [6].

FDA FAERS and Sentinel System Data

The FDA Sentinel System, which analyzes real-world claims data from over 100 million covered lives, has been used to monitor testosterone product safety signals on an ongoing basis [11]. Signals examined have included VTE, major adverse cardiovascular events (MACE), and polycythemia-related complications.

A Sentinel analysis published through FDA's Mini-Sentinel program found a 1.26-fold increase in VTE risk in new testosterone users compared to matched non-users, consistent with the label warning [11]. This finding applied to injectable and non-injectable formulations without statistically significant differences between delivery routes.

Cardiovascular Outcomes: The TRAVERSE Trial

The TRAVERSE trial (N=5,246, published 2023) was a randomized, placebo-controlled trial specifically designed to assess cardiovascular safety of testosterone replacement in men aged 45 to 80 with hypogonadism and elevated cardiovascular risk [12]. The primary outcome was MACE (cardiovascular death, non-fatal MI, non-fatal stroke).

TRAVERSE found that testosterone therapy was non-inferior to placebo for MACE over a median follow-up of 33 months (HR 0.96; 95% CI 0.78 to 1.17) [12]. The trial did, however, report a higher rate of pulmonary embolism in the testosterone group (0.9% vs. 0.5%, P<0.05) and a higher rate of atrial fibrillation [12]. These findings are expected to prompt FDA to revisit the current label's cardiovascular language, and the agency's review was ongoing as of this article's publication date.

Polycythemia as the Most Common Adverse Effect

Across FAERS reports and clinical registry data, polycythemia (hematocrit exceeding 52 to 54%) is the most frequently documented adverse effect of injectable testosterone products, including cypionate [8]. A 2017 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (27 RCTs, N=2,448) found a relative risk of polycythemia of 3.67 (95% CI 1.82 to 7.39) with testosterone vs. Placebo [13]. The risk is higher with injectable formulations than with transdermal products, because injections produce larger peak serum concentrations.

How Does Testosterone Cypionate Compare to Other Approved Testosterone Formulations?

Testosterone cypionate is one of several FDA-approved testosterone delivery systems. Each carries a shared class label but differs in pharmacokinetics, route, and practical use patterns.

Approved Testosterone Formulations in the US

| Formulation | Example Brand | Route | Approval Status | |---|---|---|---| | Testosterone cypionate | Depo-Testosterone | IM injection | FDA-approved (NDA 013753) | | Testosterone enanthate | Delatestryl | IM injection | FDA-approved | | Testosterone undecanoate | Aveed | IM injection | FDA-approved (REMS required) | | Testosterone gel 1% | AndroGel | Transdermal | FDA-approved | | Testosterone patch | Androderm | Transdermal | FDA-approved | | Testosterone pellets | Testopel | Subcutaneous | FDA-approved | | Testosterone nasal gel | Natesto | Intranasal | FDA-approved |

Why Testosterone Undecanoate Requires a REMS

Testosterone undecanoate (Aveed) carries a Risk Evaluation and Mitigation Strategy (REMS) because of a higher reported rate of POME reactions per injection compared to cypionate [5]. Testosterone cypionate does not currently require a REMS, though FDA label language requires that cypionate injections be given in settings capable of managing serious reactions [1]. This distinction is clinically meaningful: cypionate can be self-administered at home by patients trained in injection technique, while Aveed must be given in a healthcare facility [5].

Serum Half-Life Differences

Testosterone cypionate has a serum half-life of approximately 8 days, compared to 4.5 days for testosterone enanthate and roughly 90 days for subcutaneous pellets [2]. The longer half-life of cypionate relative to enanthate means fewer injections per month to maintain stable trough levels, which is one reason cypionate has remained the dominant injectable formulation in US clinical practice.

What Are the Current Prescribing Guidelines for Testosterone Cypionate?

Clinical guidelines from the Endocrine Society, the American Urological Association (AUA), and the American Association of Clinical Endocrinologists (AACE) all address testosterone cypionate prescribing within their broader testosterone therapy frameworks.

Endocrine Society 2018 Guideline

The 2018 Endocrine Society Clinical Practice Guideline on Male Hypogonadism recommends confirming the diagnosis of hypogonadism with at least two morning total testosterone measurements below the normal range (generally <300 ng/dL) before initiating treatment [8]. The guideline supports testosterone cypionate as a first-line injectable option and recommends monitoring serum testosterone 3 to 6 months after initiation, targeting mid-normal range values [8].

The guideline also states: "In men who want to preserve fertility or who are of reproductive age, we suggest against starting testosterone therapy and suggest offering gonadotropin treatment or other treatments to achieve fertility goals first" [8].

AUA Testosterone Deficiency Guidelines (2022)

The American Urological Association updated its testosterone deficiency guidelines in 2022, lowering the diagnostic threshold language to emphasize symptoms alongside biochemical confirmation [14]. The AUA guidance supports testosterone cypionate use and specifies that hematocrit above 54% should prompt dose reduction or temporary cessation rather than automatic permanent discontinuation [14].

AACE Position on Cardiovascular Monitoring

The American Association of Clinical Endocrinologists recommends baseline cardiovascular risk assessment before initiating testosterone therapy in men over 40 or those with known cardiovascular risk factors [15]. This includes a baseline electrocardiogram, lipid panel, and blood pressure documentation, none of which are formally required by the FDA label but are considered standard of care [15].

The HealthRX clinical team uses a structured pre-treatment checklist for all testosterone cypionate candidates: two fasting morning total testosterone levels drawn before 10 AM, baseline hematocrit, PSA (in men over 40), lipid panel, blood pressure, and a symptom severity score using the Aging Males Symptoms (AMS) scale. Dose initiation starts at 100 mg IM weekly rather than the label's maximum of 400 mg every 2 to 4 weeks, with titration guided by 4-week trough levels drawn immediately before the next injection.

What Is the Regulatory Status of Testosterone Cypionate for Women and Gender-Affirming Care?

Testosterone cypionate is not FDA-approved for use in women for any indication, and no NDA or supplemental NDA has been approved for this population [1]. Despite this, off-label prescribing of testosterone cypionate in women is common, particularly for hypoactive sexual desire disorder (HSDD) and as part of gender-affirming hormone therapy for transgender men.

Off-Label Use in Women

The Endocrine Society 2019 guideline on androgen therapy in women acknowledges the evidence base for testosterone in female HSDD but notes the absence of an FDA-approved product [7]. The guideline states that if testosterone is prescribed off-label for women, doses should target the upper limit of the female physiologic range (approximately 70 ng/dL total testosterone) and monitoring should occur at 3 to 6 weeks and 3 to 6 months [7].

The absence of an approved female indication means no pharmaceutical manufacturer has submitted efficacy and safety data in women adequate to support labeling. Women who receive testosterone cypionate do so under off-label prescribing, and their providers bear full clinical and legal responsibility for that decision [7].

Gender-Affirming Use

The World Professional Association for Transgender Health (WPATH) Standards of Care Version 8 (2022) describes testosterone therapy for transgender men and non-binary individuals assigned female at birth as medically necessary for appropriately assessed candidates [16]. Testosterone cypionate is one of the most commonly used formulations in this context. WPATH recommends monitoring total testosterone levels quarterly during the first year, targeting male physiologic ranges [16].

Neither FDA approval nor a specific NDA governs this use. Prescribers rely on off-label authority, and no boxed warning specifically addresses gender-affirming use. The standard cardiovascular, hematologic, and hepatic monitoring requirements apply equally in this population [16].

Testosterone Cypionate Safety: What Monitoring Does the FDA Label Require?

The current prescribing information specifies a monitoring schedule that differs somewhat from what clinical guidelines recommend. Knowing both is essential for safe prescribing.

FDA Label-Specified Monitoring

The FDA label for testosterone cypionate requires [1]:

• Serum testosterone measurement periodically during therapy.
• Hematocrit at baseline and at 3 to 6 months, then annually.
• Liver function tests if hepatic disease is suspected.
• PSA monitoring in men with known or suspected prostate cancer (testosterone is contraindicated in this group).
• Bone mineral density assessment in men with hypogonadism-associated osteoporosis.

Serum Testosterone Targets

The label does not specify a numeric serum testosterone target, referring only to maintaining levels "within the normal range." The Endocrine Society guideline fills this gap, recommending mid-normal range targets (400 to 700 ng/dL total testosterone) when using injectable formulations, with trough levels drawn just before the next scheduled injection [8].

A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,114 men on testosterone therapy) found that 34% of men on 200 mg testosterone cypionate every 2 weeks had trough total testosterone levels below 300 ng/dL, indicating the standard biweekly schedule is insufficient for many patients [2]. This data supports the growing clinical practice of weekly dosing, though it remains outside the letter of the label.